全反式维甲酸对防治经皮冠脉介入治疗后再狭窄的临床疗效观察

目的观察不同剂量全反式维甲酸（ATRA）对防治经皮冠脉介入治疗（PCI）后再狭窄（Rs）的疗效。方法2004年7月至2005年9月连续入院行PCI的冠心病300例。随机分为全反式维甲酸正常剂量组（10mgt．i．d p．o，甲组）、强化剂量组（20mgt．i．d p．o，乙组）、对照组（丙组）。6个月后分别比较甲乙丙三组的再狭窄率、心脏事件发生率和心功能。结果300例患者中男性228例、女性72例。住院期间甲乙丙三组比较：心绞痛9％VS8％VS9％；再次急性心肌梗死（AMI）O％VS2％VS1％；再次缺血性血运重建（TVR）3％VS2％VS3％；心源性死亡4％VS6％VS4％，P〉0．05，无显著统计学差异。随访期间三组比较：心绞痛12％VS9％VS20％；再次AMII％VSO％VS1％；心源性死亡2％VS4％VS4％，P〉0．05，无显著统计学差异；再狭窄率3／33（9．1％）VS2／30（6．7％）VS12／32（37．5％）；TVR3％VS2％VS11％，P〈0．05，有显著统计学差异。结论常规剂量ATRA防治再狭窄安全有效。     

脑出血后的抑制细胞凋亡干预

脑出血后血肿周围组织可发生继发性损伤。研究表明，细胞凋亡在脑出血后继发性损伤中起着重要作用。抑制细胞凋亡可显著改善脑出血后的神经功能缺损。     

Percutaneous coronary intervention in two occluded arms of a saphenous 'Y'-graft: the importance of protecting both of your arms.

Percutaneous intervention in saphenous vein grafts (SVG) carries a higher risk of distal embolization than intervention in a native vessel, and use of a distal protection device has been shown to improve the outcomes in SVG interventions. We describe an intervention done in an unexpected 'Y' SVG which required dual distal protection with Filterwires placed in both limbs of the diseased graft and which was performed via a 6 Fr guide catheter.     

Current concept and future research directions of mild cognitive impairment

Alzheimer's disease (AD) generally begins with mild memory problems which occur in an insidious manner and progresses to the development of multiple cognitive impairments. There is a ‘gray’ area between what is classified as ‘normal’ and what is classified as ‘dementia’, currently called mild cognitive impairment (MCI). In this article, a case of MCI is described, and the diagnosis, assessment, subclassification (pre‐Alzheimer type and white matter lesion type) and future therapeutic plans for MCI are reviewed.     

性倒错：大丈夫变娇娇娇娘

“你太不懂女人了！”每次吵架妻子都会甩给他这句话，这让他产生了破解女人密码的强烈愿望。[编者按]     

自杀行为及其干预的研究进展

自杀已经成为一个世界范围内的重大公共卫生问题。中国的自杀特征具有独特性。自杀行为的发生往往是内在因素与外部因素相互作用的结果，它与社会学、心理学、伦理学、生物学、精神病学等各方面密切相关。自杀原因虽然错综复杂，但我们要提高意识，认识到自杀是一种可以预防的公共卫生问题。     

血管介入仿真模拟器在心血管医生冠状动脉介入技术规范化培训中的作用

目的明确Angiomemor（美国Simbionix公司生产）血管介入仿真模拟器是否有助于冠状动脉造影技术的掌握和提高。方法选取16名无血管放射介入经验的心血管医生，接受相同课时的冠状动脉介入造影理论培训后，按随机表编码随机分为模拟器培训组与非培训组各8名，模拟器培训组8名医生接受Angiomemor血管介入仿真模拟器培训，模拟冠状动脉造影操作，非培训组8名心血管医生未接受仿真模拟器培训。在随后的真实临床环境中操作冠状动脉造影时，评价2组医生冠状动脉造影操作过程中错误的频数、平均造影时间、造影剂使用量及术中放射线剂量。结果相对于非培训组，模拟器培训组医生在冠状动脉造影操作中错误频数减少62．5％、平均造影时间减少44．0％、造影剂使用量减少44．0％，术中平均放射线曝光时间减少了57．7％，平均X线累计曝光剂量减少51．6％，单位面积X线累计曝光剂量减少了52．4％。结论Angiomemor血管介入仿真模拟器有助于医生较快地熟练掌握冠状动脉造影技术，是冠状动脉介入规范化培训的重要辅助手段之一。     

急性脑梗死选择性动脉溶栓治疗与护理

综述了急性脑梗死选择性动脉溶栓治疗与护理,详细介绍了脑梗死的发病机理、溶栓时机、适应证、介入治疗方法及护理.     

男性病人冠状动脉病变与吸烟关系的研究

[目的]探讨吸烟对病人冠状动脉病变的影响。[方法]对吸烟组(5 0例)与不吸烟组(3 0例)进行冠状动脉造影,观察记录冠状动脉病变情况并进行统计学分析。[结果]两组冠状动脉病变记分、每日不同吸烟量与冠状动脉病变记分、不同的吸烟年限与冠状动脉病变记分比较均有统计学意义(P <0 .0 1)。[结论]长期吸烟可使冠状动脉病变程度加重,应加强对长期吸烟及冠状动脉介入术后病人的健康教育,有效预防和控制冠心病,提高人群的健康水平。     

Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson's disease patients: the effects of an early therapeutic intervention

To evaluate the long-term effects of entacapone on both mean daily 'on' time and health-related quality of life (QoL) in patients with Parkinson's disease (PD) experiencing 'end-of-dose' motor fluctuations and the benefits of an early therapeutic intervention. A prospective, multicenter, observational, 12-month study was performed with an initial 3-month intervention phase, consisting of a phone call to half of the patients from randomly selected investigators to assess if dose adjustment was necessary. Effectiveness was determined by home diaries ('on' time), subscales II and III of the Unified Parkinson's Disease Rating Scale (UPDRS), and the Parkinson's Disease Questionnaire (PDQ-8). After 3 months of treatment, 4.0% of the intervention group patients discontinued the study, versus 18.4% in the control group ( P  < 0.01). The improvement in 'on' time was significantly increased since the 3-month visit (21%, P  < 0.0001) until the end of the study (23% at 12 months, P  < 0.0001). Entacapone also induced significant reductions in the UPDRS scores for subscales II and III and in the PDQ-8 score. 11.2% of patients experienced at least one adverse reaction. This study confirms the effectiveness of entacapone in reducing motor fluctuations by increasing 'on' time, and in improving QoL of PD patients. An early adjustment of entacapone and levodopa doses reduces the number of treatment discontinuations during the first months of treatment.